Energy and protein intake in medical and geriatric inpatients with MEDPass versus conventional administration of oral nutritional supplements: study protocol for the randomized controlled MEDPass Trial by Reber, Emilie et al.
STUDY PROTOCOL Open Access
Energy and protein intake in medical and
geriatric inpatients with MEDPass versus
conventional administration of oral
nutritional supplements: study protocol for
the randomized controlled MEDPass Trial
Silvia Kurmann1* , Emilie Reber2, Maria F. Vasiloglou3, Philipp Schuetz4, Andreas W. Schoenenberger5,
Katja Uhlmann1, Anna-Barbara Sterchi2 and Zeno Stanga2
Abstract
Background: Disease-related malnutrition is highly prevalent in hospitalized medical and geriatric inpatients. It is
associated with negative outcomes such as muscle wasting, decline of functional status, and increased morbidity
and mortality. Oral nutritional supplements (ONS) are frequently used in nutritional therapy to increase intake.
However, compliance to ONS is often limited and maybe improved by prescribing ONS in small portions timed
with the medication (MEDPass). However, it is unknown whether the MEDPass administration enhances patients’
total energy and protein intake.
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Methods: The MEDPass Trial is a randomized, controlled, open-label superiority trial. Patients in the MEDPass
group receive 50 ml of ONS four times per day, distributed with the medication rounds. Patients in the
control group receive ONS between meals. The primary outcome is average daily energy intake (% of
calculated daily requirement). For our power analysis, we assumed that administration of ONS in the
MEDPass administration mode increases energy intake by at least 10% (i.e., by 200 kcal for an average
energy requirement of 2200 kcal/day). Thus, with the inclusion of 200 patients, this trial has 80% power to
demonstrate that intervention group patients have an average intake of 2200 kcal/day (SD 500 kcal) versus
2000 kcal/day (SD 500 kcal) in control group patients. Energy and protein intakes from ONS and all food
consumed are monitored continuously throughout the hospital stay and are statistically compared to the
patient’s requirements. Secondary outcomes include average daily protein intake (% of calculated daily
requirement), average intake of ONS/day, the course of body weight, handgrip strength, appetite, and
nausea. Furthermore, hospital length of stay and 30-day mortality are assessed. The primary statistical
analysis will be performed as an intention-to-treat analysis adjusted for the stratification factors used in
randomization.
Discussion: To our knowledge, this is the first randomized controlled trial assessing total energy and
protein intake for the entire hospitalization period in patients receiving MEDPass versus conventional ONS
administration. Thus, the MEDPass Trial will fill a gap and answer this relevant clinical question.
Trial registration: ClinicalTrials.gov NCT03761680. Registered on 3 December 2018. Kofam.ch SNCTP0000031
91. Registered on 15 October 2018
Keywords: Oral nutritional supplements, Energy intake, Protein intake, Malnutrition, MEDPass, Nutrition as
medication, Medication rounds
Background
Disease-related malnutrition (DRM) in hospitalized pa-
tients is a common problem with an estimated prevalence
of 20–60% [1–3]. DRM is associated with detrimental
clinical and metabolic consequences, such as catabolism,
muscle wasting, impaired muscle function, and mobility
[4, 5]. DRM is also associated with higher mortality and
morbidity rates and increased hospital length of stay
(LOS) [3, 4, 6]. These outcomes not only affect quality of
care, but also pose a substantial economic burden [3].
In inpatients at nutritional risk, an adequate and early
nutritional therapy has been shown to be effective, sig-
nificantly reducing severe complications and 30-day
mortality [6, 7]. Oral nutritional supplements (ONS) are
one of the most common treatments for DRM, and
ONS are designed for this specific medical purpose [8,
9]. The use of ONS has proven efficient and cost-
effective [10, 11]. Treatment with ONS may reduce mor-
tality and complications, attenuate or prevent muscle
loss, and improve nutritional status and function [10, 12,
13]. The European Society of Clinical Nutrition and Me-
tabolism (ESPEN) recommends the use of ONS for med-
ical and geriatric patients at nutritional risk [10, 14].
These patients often live with chronic illness, which is
associated with appetite and body weight loss. Thus, the
risk of DRM is increased [10].
Compliance with ONS is often described as suboptimal.
This poses a barrier to adequate oral nutrition therapy
[14, 15]. The ONS administration mode may be one of
the keys to improving compliance. There are no standards
on how to administer ONS in terms of timing and dose
throughout the day, which leads to individual approaches.
In the hospital setting, ONS are conventionally served by
nurses, nursing aids, or catering personnel between main
meals. The MEDPass administration mode offers a differ-
ent approach, in which ONS are distributed on medica-
tion rounds three or four times per day in unusually small
portions (50–120ml) [16–22]. Preliminary trials suggest
that the MEDPass administration mode improves compli-
ance and cost effectiveness [17, 19, 22, 23].
However, since ONS are dense in energy and protein,
they may have a negative impact on appetite [24]. Conse-
quently, enhancing compliance with ONS may not auto-
matically lead to improved nutritional intake throughout
the day because conventional food intake may decline.
Therefore, this trial will study total energy and protein in-
take throughout the day as primary outcome measures
when ONS are administered in the MEDPass mode versus
the conventional administration mode. To our knowledge,
there has never been a prospective trial in which total en-
ergy and protein intake was studied consistently and sys-
tematically. Therefore, the aim of this trial is to fill this
clinically relevant gap of knowledge.
Methods
Study design
The MEDPass Trial is a randomized, controlled, clinical
trial (RCT) conducted with parallel groups. Blinding of
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patients is not possible because of the evident differences
in ONS administration times. Therefore, it is conducted
as an open-label RCT. The MEDPass Trial is a superior-
ity trial. The allocation ratio of intervention group and
control group is 1:1.
Study population
The MEDPass Trial includes medical as well as geriatric
inpatients at the Tiefenau facility of the University Hos-
pital of Bern. It includes inpatients of the Department of
Geriatrics and the Department of General Internal
Medicine who meet the eligibility criteria listed in
Table 1.
Study intervention and comparator
Every patient in the MEDPass group receives 50 ml of
ONS four times per day distributed by the registered
nurses (RN) on the ward during medication rounds.
Three out of the four medication rounds occur approxi-
mately 30 min before the main meals’ distribution, and
the evening medication round is at 10 pm. Patients are
counseled to take the ONS directly at the start of the
meal to avoid any possible interaction with medications.
The control group regimen was chosen to compare the
MEDPass administration mode to usual clinical practice.
Usual practice of ONS administration at the study site is
unstandardized. This kind of prescription may range
from one up to four bottles of ONS per day and is
served between the meals or after the evening meal. Pa-
tients in the control group receive ONS between meals
according to unstandardized prescriptions. The staff was
instructed not to make any changes to the procedures
followed before the initiation of the trial. This means
that the amount of ONS prescribed to control group pa-
tients might be higher than those of the intervention
group. However, compliance with ONS may be better
with the MEDPass-mode. Compliance in the context of
the MEDPass Trial is defined as the percentage of pre-
scribed ONS consumed. Furthermore, patients receiving
ONS in the MEDPass administration mode may be able
to eat more additional food between meals than those
receiving ONS between meals. Thus, we hypothesize
that MEDPass group patients are more likely to reach
their energy and protein targets even if their net pre-
scription of ONS is lower.
Type of ONS used in the MEDPass trial
All ONS used in this trial are selected according to pa-
tients’ nutritional needs and flavor preferences. Patients
may choose from a wide range of available products at
University Hospital of Bern. All products with an energy
density of 1.5 kcal/ml and 2 kcal/ml are included in this
trial. Overall, eight different ONS with this energy dens-
ity are in stock. The amount of protein in these ONS
ranges from 4 to 10 g/100 ml. Six of the ONS are nutri-
tionally complete. Two of them do not contain any fat.
The ONS are from different providers (Abbott Nutrition,
Fresenius Kabi, Nestlé Health Science). If patients re-
quire an ONS that is not available in the standard as-
sortment of the University Hospital, it can be ordered if
it is obtainable on the Swiss market.
Ethical aspects
The study is carried out in accordance with the current
version of the World Medical Association Declaration of
Helsinki protocol [26], ICH-GCP guidelines [27, 28] or
ISO 14155 norm [29] and according to the Swiss Federal
Act on Research involving Human Beings [30, 31].
Randomization
Randomization is stratified according to the NRS 2002
total score and the energy content of the ONS (kcal/ml).
The NRS 2002 total score is stratified as NRS 3, NRS 4,
or NRS 5-7. The energy content of the ONS is stratified
as either 1.5 kcal/ml or 2 kcal/ml. Even distribution of
these factors between the groups minimizes bias since
they may directly influence primary and secondary out-
come parameters. Randomization is conducted using the
Research Electronic Data Capture (REDCap®) program
(Vanderbilt University, Nashville, TN, USA, 2020,
Table 1 Inclusion and exclusion criteria
Inclusion criteria • Nutritional Risk Screening (NRS 2002) total score ≥ 3 points according to routine screening at admission within 72 h [25]
• Expected hospital LOS ≥ 3 days after screening (as estimated by the treating physician)
• Patient qualifies for ONS and approves prescription
• Age > 18 years
• Willingness and ability to provide informed consent
Exclusion criteria • Initially admitted to critical care unit
• Immediate post-operative phase (< 7 days post-surgery)
• Dysphagia with the inability to swallow liquids
• Admitted with or scheduled for supplemental or total enteral nutrition and/or parenteral nutrition
• Mini Mental State examination < 16 points
• Hospitalization due to anorexia nervosa, acute pancreatitis, or acute liver failure
• Patients with cystic fibrosis, short bowel syndrome, or after gastric bypass surgery
• Terminal condition (end of life situation)
• Poor German language skills (study language)
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version 9.1.15). Registered Dietitians (RD) input the
stratification data and randomize electronically within
the REDCap® program. The RDs do not have access to
the concealed randomization sequence. The
randomization list with random numbers for coding was
pre-specified by the Clinical Trial Unit (CTU) Bern and
electronically integrated into the REDCap® database.
Outcomes
The primary outcome is the average energy intake/day
(kcal, % of calculated daily requirement). Secondary out-
comes include average protein intake/day (g, % of calcu-
lated daily requirement), average ONS intake/day (ml),
the course of handgrip strength (kg), body weight (kg),
appetite, and nausea. Furthermore, hospital LOS and 30-
day mortality are assessed.
Study conduct and data collection
Participants are recruited consecutively. Based on rou-
tine screening upon admission, patients with an NRS
2002 total score of > 3 are referred to the RDs [25, 32].
The RDs check the eligibility criteria. If there is an indi-
cation but no ONS prescribed, the RDs counsel the pa-
tient concerning ONS. Once an eligible patient agrees to
a prescription of ONS and an appropriate product is se-
lected, the patient is informed by the RD about the pos-
sibility of participating in the trial. Upon approval, the
RD obtains informed consent and randomizes the pa-
tient. The prescription of ONS is carried out by the
medical doctors (MD). All involved personnel (MDs,
nursing and catering staff) is informed by the RDs of the
patient’s participation in the trial. An overview of the pa-
tients’ flow is given in Fig. 1 and an overview of the time
schedule for participants is provided in Table 2. The trial
is only concerned with ONS administration and has no
influence on any other aspects of patients’ treatments.
ONS may be discontinued if the indication therefore no
longer exists.
The criteria for ONS discontinuation are:
 ONS is not indicated anymore due to increased food
intake
 Occurrence of a serious adverse event (SAE) that
necessitates a halt to the prescription
The reasons for discontinuation are documented. Fur-
thermore, withdrawal from the trial is possible at any
time at the patients’ request.
All data is inputted manually by the RDs into REDCap.
REDCap is a program that provides the highest standard
of data protection and an internal back-up system is in
place to prevent data loss. The REDCap study database
with all archive tables will be securely stored by CTU
Bern for at least 15 years. The sponsor also keeps the
Trial Master File (TMF) and interim/final reports for at
least 10 years. All extracted data files are exclusively
stored on password-protected personal computers.
Source data is collected mostly from the electronic
health record (EHR). This includes the NRS 2002, in-
and exclusion criteria, patient characteristics, ONS in-
take, body weight, LOS, and safety outcomes. Meal
cards, forms for collecting data on food intake between
the meals and protein and energy intake calculations,
are printed out and input manually into REDCap by the
RDs. All trial-related paper documents are locked in a
specific cabinet in the RD’s office during the whole study
period. Afterwards, this material will be stored safely for
10 years in the locked archive of the Department of
Endocrinology, Diabetes, Nutritional Medicine, and Me-
tabolism at Bern University Hospital.
All participating staff have received formal training for
all their tasks, and training materials are available on site
on the intranet platform. Furthermore, training is pro-
vided continuously due to staff turnover. Regular ex-
change with appointed members of nursing and medical
staff is implemented to monitor adherence to the proto-
col. The MEDPass Trial is managed and overseen by the
study steering committee, the dietetic committee, and
the data management committee. The study steering
committee (authors SK, ER, PS, AWS, ABS, and ZS) is
responsible throughout for main decisions on conduct
including risk management, reports to the Competent
Ethics Committee (CEC), and results dissemination. The
study steering committee may bring forward suggestions
for protocol amendments. If approved by the committee,
they will be reported to the CEC. Substantial amend-
ments are only implemented after CEC approval.
Under emergency circumstances, deviations from the
protocol to protect the rights, safety, and wellbeing of
human subjects may proceed without prior approval of
the sponsor, the study steering committee, and the CEC.
Such deviations shall be documented and reported to
the sponsor, the steering committee, and the CEC as
soon as possible.
All non-substantial amendments are communicated to
the CEC within the Annual Safety Report (ASR). The
trial registries will be updated within 30 days. Trial par-
ticipants will be contacted via written communication
and will be given the possibility to withdraw their
approval.
The dietetic committee (authors SK, ABS and the
team of RDs on site) oversee the implementation of re-
cruitment, data collection, and the ongoing training ses-
sions. The data management committee (authors SK,
ER, MV, PS, AWS, and ZS) monitor data quality and are
responsible for the statistical plan. During the recruit-
ment period, an independent employee from Bern
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University of Applied Sciences will act as monitor, con-
ducting at least one monitoring visit of the trial on site.
The frequency and duration of the visits are dependent
on the rate of subject enrollment, the quality of the
study documents and the findings. During the visit(s),
the monitor will check whether the trial is being carried
out according to the study protocol and whether the
subjects’ safety and rights are being protected. Further-
more, the monitor will review the collected trial data
and verify source documents. The sponsor and the prin-
cipal investigator on site allow the monitor direct access
to all relevant documents during visits. They also agree
to allocate their time and the time of their staff to the
monitor to discuss findings and any other relevant
issues.
In case of discrepancies, the monitor will make recom-
mendations and schedule visits at shorter intervals. For
each contact, a report is completed and signed by the
monitor and the sponsor.
As category A trials are exempt from providing insur-
ance, there is no specific insurance policy in place. How-
ever, general liability insurance is provided by Inselspital,
Bern University Hospital.
Measurements
Energy, protein, and ONS intake
All parameters are assessed continuously until dis-
charge or for a maximum of 30 days (Table 2). The
RDs calculate daily energy and protein requirements
according to relevant current clinical nutrition guide-
lines that apply to the patients in the MEDPass Trial
[10, 14, 33]. The formula per patient is chosen ac-
cording to age and body mass index (BMI). As some
patients may suffer from progressive renal failure, the
Clinical Practice Guideline of the National Kidney
Foundation is used to calculate these patients’ protein
needs [34]. The formulas for daily energy require-
ments as related to the primary outcome are listed in
Table 3.
Recommended protein intake is calculated according
to the guidelines for geriatric and medical patients using
the formula 1 g/kg body weight/day [10, 14, 33]. How-
ever, patients with chronic kidney disease and estimated
glomerular filtration rate (eGFR) < 30mL/min/1.73m2,
who are not on dialysis, are an exception. In this case,
the actual body weight is multiplied by 0.8 g/kg body
weight/day [34].
Detailed data concerning food intake is assessed after
every meal. Each component of every meal is evaluated
separately by the personnel collecting the tray after the
meal. More specifically, the consumed percentage (100%,
75%, 50%, 25%, or 0%) of any delivered food component
is evaluated and the value is noted accordingly on the
meal card. Furthermore, after each meal, patients are
Fig. 1 Patients’ flow. NRS 2002, Nutritional Risk Screening 2002; ONS,
oral nutritional supplement; RD, registered dietitian; SAE, serious
adverse event
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interviewed on food intake between the main meals. To
keep track of intake in addition to meals, a separate
document is used. It is distributed and collected during
morning meal rounds. All food intake documentation is
temporarily stored at ward level and collected daily by
the RDs from Monday to Friday. For the weekends, it is
collected on Mondays. If data points are missing, the
RDs interview the patient directly to fill the respective
data gaps. All meals at the facility are prepared accord-
ing to recipes of the Bern University Hospital database.
Energy and protein intakes are primarily calculated via
the electronic menu system LogiMen® (Kretschmer-Kel-
ler Leonberg, Germany, 2016, version 5.4). The system
contains energy and protein content data for all hospital
meals and snacks. This method ensures high calculation
accuracy as the recipes are integrated in the system. En-
ergy and protein intake from food items that are not
registered in the LogiMen® system are calculated by the
RDs using nut.s nutritional software® (dato Denkwerk-
zeuge, Vienna, Austria, 2008, version 1.32.74). All meal
cards and calculations are sent to one of the co-
investigators, who is blinded to patient allocation, for
recalculation.
The amount of ONS consumed is monitored daily by
the RNs by measuring the amount consumed with a
measuring cup. In the trial setting, ONS is prescribed
and listed in the medication chart in the EHR. All medi-
cations are listed with the amount prescribed. The
amount consumed is documented on a standardized
basis for all medications. The consumed amount is doc-
umented in the EHR with an accuracy of ± 5 ml. From
this assessment, the RDs calculate energy and protein in-
take from ONS.
Handgrip strength
Handgrip strength is assessed by the RDs on study visits
2–6 (Table 2) until discharge or for a maximum of 30
days (Table 2). Handgrip strength is evaluated using the
JAMAR® Hydraulic Hand Dynamometer (Patterson
Medical, Warrenville, IL, USA) with an accuracy of ±
0.5 kg. The measurement is always conducted according
to the same procedure and on the same hand. If pos-
sible, the measurement is performed on the dominant
hand. To ensure data validity, the measurement is taken
three times with a break of at least 30 s between mea-
surements and the highest value is noted [35].
Table 2 Time schedule for participants
Study period Screening Intervention period Evaluation Follow-up
Visit 1 2 3 4 5 6
Day 0 1 8 15 22 29 * **
NRS 2002 total score x
NRS 2002 subscore nutritional status x
Inclusion and exclusion criteria x
Information, informed consent x
Assignment to study group x
Baseline patient characteristics x
Energy intake/day (kcal)** Continuous assessment
Protein intake/day (g)**
ONS intake/day (ml)**
Serious adverse events (SAE)**
Handgrip strength (kg) x x*** x*** x*** x***
Body weight (kg) x x*** x*** x*** x***
Body height (cm) x
BMI (kg/m2) x
Appetite (VAS) x x*** x*** x*** x***
Nausea (VAS) x x*** x*** x*** x***
Procedural variables x
Hospital LOS (d) x
30-day mortality (y/n) x
*After patient dismissal or after 30 days of inclusion
**For 30 days upon inclusion
***Assessment at day 1, day 8, day 15, day 22, and day 29
Visits 2–6: study visits may be conducted earlier or later by a maximum of 2 days
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Body weight
Body weight is monitored as part of standard clinical
practice by the nursing staff with an accuracy of ± 0.1 kg.
Immobile patients are weighed on the seca® wheelchair
scale (Vogel & Halke, Germany, model 665) and mobile
patients on the sitting scale seca® (Vogel & Halke,
Germany, model 959). Body weight measurements are
prescribed by the MDs according to the study schedule
(Table 2) directly after patient enrolment in the trial.
RDs evaluate if body weight measurements are accurate
according to the patient’s clinical status and medications.
RDs may contact the MDs to discuss the validity in case
of uncertainty.
Appetite and nausea
The course of appetite and nausea are recorded by the
RDs during weekly study visits (Table 2). The level of
appetite and nausea on the current day are the focus of
the assessment. The assessment is carried out by asking
the patient to scale the level of appetite/nausea using a
visual analog scale (VAS). The scale visible to the patient
only has smileys. The scale on the backside of the smiley
scale ranges from 0 to 10 cm so that the subjective
measurement can be objectified with an accuracy of ±
0.1 cm.
Hospital LOS and 30-day mortality
One of the co-investigators evaluates hospital LOS and
30-day mortality after the participants are released from
the hospital or after 30 days of trial inclusion respectively
(Table 2). Hospital LOS is assessed from the EHR as
number of days: the calculation excludes the day of hos-
pital discharge [36]. Hospital LOS is only assessed in
medical inpatients since the geriatric inpatients have a
prefixed duration of stay. Assessment of 30-day mortal-
ity is done by phone call to the patients’ home or the in-
stitution where the patient was referred to. If the patient
is still hospitalized, the information is available in the
EHR.
Baseline patient characteristics and procedural variables
The following baseline patient characteristics are re-
corded by RDs during visit 1 (Table 2):
✓ Disease categories for main diagnosis
(gastrointestinal disease, infectious disease,
cardiovascular disease, neurological disease, oncologic
disease, other diseases)
✓ Department in which the patient is hospitalized
✓ Gender (male, female)
✓ Age (years)
✓ Energy content per ml ONS (1.5 kcal/ml or 2 kcal/ml)
✓ NRS 2002 total score
✓ NRS 2002 subscore for impaired nutritional status
✓ Body weight (kg)
✓ Body height (cm)
✓ BMI (kg/m2)
The following procedural variables are recorded after
discharge by one of the co-investigators:
✓ Number of days from trial inclusion to hospital
discharge
✓ Number of days with prescribed ONS
✓ Number of days with energy and protein intake
monitoring
✓ Compliance versus non-compliance with the study
protocol
✓ Number of meals at which patients were nil per os
during energy and protein intake assessment (meals at
which patients are not allowed to eat for medical reasons)
✓ Number of meals at which food intake could not be
assessed
✓ Involvement of RDs in the treatment of the patients
Safety outcomes
As defined by Good Clinical Practice (GCP) [27], SAEs
are monitored and investigated continuously. Potential
SAEs in this trial are pneumonia caused by ONS aspir-
ation and death associated with pneumonia caused by
ONS intake in the MEDPass-mode.
Statistical analysis
Hypothesis
Working hypothesis We hypothesize that patients in
the intervention group (MEDPass mode) consume more
energy as compared to patients in the control group.
Null hypothesis (Ho) There is no difference in energy
intake between the groups.
Sample size calculation
Based on our clinical experience, we assumed for our
power analysis that administration of ONS in the MED-
Pass mode increases energy intake (primary endpoint)
by at least 10% (i.e., by 200 kcal from an average of 2000
kcal/day). Furthermore, we assumed that an average pa-
tient weighs 75 kg and therefore has an approximate en-
ergy requirement of 2200 kcal. A final assumption is that
Table 3 Calculation of daily energy requirements
Formulas for daily energy requirements
BMI < 18.5 kg/m2 BMI > 18.5 kg/m2
< 65
years
Actual body weight × 30
kcal [10]




Actual body weight × 32
kcal [14]
Actual body weight × 30 kcal
[14, 33]
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in current clinical practice they may only receive 2000
kcal/day. Therefore, to demonstrate that intervention
group patients have an increased average daily energy in-
take of 200 kcal/day (i.e., from 2000 (SD 500 kcal) to
2200 (SD500 kcal)), we need to include 200 patients to
achieve 80% power (alpha error of 0.05). The power cal-
culation used the sampsi command in STATA® (Stata
Corp, USA, 2017, version 15.3). Importantly, this trial is
not powered to investigate whether the difference in en-
ergy intake of 200 kcal/day makes a significant difference
to clinical outcomes. However, a similar increase in en-
ergy intake has previously shown to decrease the risk of
adverse outcome and mortality [7].
Primary analysis
The baseline patient characteristics will be summarized
for both groups. The primary analysis will be performed
as an intention-to-treat (ITT) analysis including all ran-
domized patients regardless of protocol adherence. In a
further step, we will also do a per-protocol analysis ex-
cluding patients with major protocol violations as out-
lined below.
For the primary outcome, we will test whether MED-
Pass administration is superior to usual care and com-
pare the average amount of daily energy intake using a
Student’s t test or chi-square test. We will also fit linear
regression models adjusted for initial NRS 2002 score
and average amount of energy in the ONS, reported ad-
justed differences (coefficients), and corresponding 95%
confidence intervals (CIs). Total energy, protein, and
ONS intake throughout the study period will be divided
by days of assessment per patient. Linear regression ana-
lysis adjusted for stratification factors will also be used
for the evaluation of average daily protein intake as com-
pared to the individual requirement (%) throughout the
hospitalization, average intake of ONS/day (ml) through-
out the hospitalization, and hospital LOS (days) between
the groups. Logistic regression analysis adjusted for
stratification factors will be is used for difference in 30-
day mortality (yes/no) between the groups. Repeated
measure models will be used for the evaluation of differ-
ences in course of handgrip strength throughout the
hospitalization, weight changes throughout the
hospitalization, and course of appetite and nausea
throughout the hospitalization. The procedural variables
will be analyzed and presented descriptively. There will
not be a statistical safety assessment since there are no




A per-protocol analysis will be conducted excluding pa-
tients who were incompliant with the study protocol
(ONS-prescription for < 80% of the days from inclusion
to discharge), patients that were nil per os for > 10% of
their meals during the time of intake monitoring, pa-
tients of which > 10% of meals could not be assessed
during the time of intake monitoring, patients that did
not receive the randomized intervention, and patients
violating any eligibility criteria.
The same parameters and tests as in the primary ana-
lysis will be assessed and conducted for this population.
Subgroup analyses
Subgroup analyses on the ITT patient set will include
mean energy and mean protein intake throughout the
hospitalization as compared to requirements. Linear re-
gression will be used and adjusted for stratification fac-
tors to enable comparison of patients by group of
different ONS energy content, different NRS 2002 sub-
score for nutritional status, different levels of appetite
and different levels of nausea on day 1, different levels of
handgrip strength at day 1, and different levels of diet-
etic involvement in patients’ nutritional care.
Trial status
Recruitment is ongoing since November 22, 2018. As of
September 8, 2020, 126 participants have been recruited.
Expected completion of recruitment according to
current projection is November 2021. The trial is con-
ducted according to the protocol version 1.2 of Novem-
ber 22, 2019.
Dissemination policy
The plans for the dissemination of the MEDPass Trial
results include a publication in an international peer-
reviewed journal, a poster presentation at one of the re-
nowned nutrition congresses such as ESPEN or NUTRI-
TION and the implementation of the results in the BSc
curriculum of Nutrition and Dietetics at Bern University
of Applied Sciences.
Discussion
The MEDPass Trial studies a broad spectrum of patients
at nutritional risk. This approach was chosen deliber-
ately to ensure representability of the results on poly-
morbid patient populations of general medical and
geriatric departments. The MEDPass Trial falls under
the category of effectiveness research [37]. Effectiveness
research aims at broadly representing the studied patient
population and compares interventions to usual clinical
practice [37]. Thus, the results of effectiveness research
support clinical decision making and may improve the
quality, effectiveness, and efficiency of health care [37].
A representative patient population as studied in the
MEDPass Trial may more efficiently support decision
making for the ONS administration mode.
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Although the polymorbid, frail patient population ac-
counts for the majority of healthcare costs, it is the least
studied population [38]. Polymorbid patients are most
often excluded from RCTs because of the complexity of
their health condition [38].
To our knowledge, the MEDPass Trial is the first RCT
in which total energy and protein intake of subjects with
MEDPass versus conventional ONS administration are
studied consistently and systematically throughout their
hospitalization. Thus, the MEDPass Trial will answer the
clinically relevant question if the MEDPass mode of ad-
ministration is superior to the conventional administra-
tion of ONS concerning total energy intake of patients.
Furthermore, it may help clinicians in their decisions on
administration mode for clinical practice.
As in any open-label trial, there is potential for per-
formance bias, as patients may be influenced by their
trial participation [39]. Compliance with ONS and nutri-
tional therapy may thus be increased [39]. In the MED-
Pass Trial, blinding of participants is not feasible due to
the obviously different times of ONS administration.
However, the recalculation of all meals by a fully blinded
co-investigator enhances objectivity, promotes data qual-
ity, and minimizes bias.
The stratification of randomization is aimed at pre-
venting statistical differences between groups due to
ONS energy density. This is a relevant approach since
differences between groups would directly affect the pri-
mary outcome. Furthermore, the stratification for NRS
2002 score is aimed at reducing differences in nutritional
risk between groups. This may reduce bias significantly
and therefore all statistics will be adjusted for both
stratification factors. The wide selection of ONS avail-
able in the institution represents daily clinical practice.
There is no influence of the financial sponsor on the se-
lection of ONS in this study.
Our initial calculation and projections predicted the
completion of patient recruitment in spring 2020. In the
course of the trial, recruiting was prolonged for various
reasons, including predominantly organizational barriers
to recruitment. Organizational barriers are frequently
described as significant for the prolongation of clinical
trials [40–42]. In patients with unscheduled admissions,
such as the majority of those in our facility’s medical de-
partment, recruitment challenges are more evident. LOS
in the medical department is usually shorter than on the
geriatric wards. This disqualifies some of the medical pa-
tients because after screening and referral, they may not
stay three more days as needed according to the eligibil-
ity criteria. Moreover, medical patients with unscheduled
hospitalizations may be too anxious about their treat-
ment, in pain, or too unwell to provide consent [42]. Re-
cruitment on the geriatric wards also presents
challenges. Reading and understanding the consent
forms may be difficult for some of the patients [41]. Fur-
thermore, distrust and/or fatigue are known barriers in
recruiting elderly patients onto clinical trials [41].
To facilitate recruitment, Kadam et al. as well as
Huang et al. suggest reducing the complexity and inter-
professional dependencies in trial setups [43, 44]. As the
management of malnutrition is a highly interprofessional
task, possibilities for reduction of complexity are scarce.
Retrospectively, one option may have been to task the
RDs to conduct the nutritional screening. In that sce-
nario, the whole process from screening to patient infor-
mation to inclusion would have been in the hands of the
RDs. This may have proved more efficient as interprofes-
sional dependencies would be reduced. 86% of clinical
trials do not reach their recruitment targets in the pro-
jected time [43]. As personal resources of all involved
professions in the MEDPass Trial are limited, prolonging
the recruitment period to reach the desired power was
the obvious course of action.
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